145 related articles for article (PubMed ID: 15460522)
1. Can modulation of viral fitness represent a target for anti-HIV-1 strategies?
Clementi M
New Microbiol; 2004 Jul; 27(3):207-14. PubMed ID: 15460522
[TBL] [Abstract][Full Text] [Related]
2. Intra-host evolution of human immunodeficiency virus type 1 and viral fitness.
Clementi M; Canducci F; Bagnarelli P; Menzo S
New Microbiol; 2004 Apr; 27(2 Suppl 1):41-4. PubMed ID: 15646063
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo.
Martinez-Picado J; Martínez MA
Virus Res; 2008 Jun; 134(1-2):104-23. PubMed ID: 18289713
[TBL] [Abstract][Full Text] [Related]
4. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
5. Viral phenotype and fitness.
Andreoni M
New Microbiol; 2004 Apr; 27(2 Suppl 1):71-6. PubMed ID: 15646067
[TBL] [Abstract][Full Text] [Related]
6. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.
Nicastri E; Sarmati L; d'Ettorre G; Palmisano L; Parisi SG; Uccella I; Rianda A; Concia E; Vullo V; Vella S; Andreoni M
J Med Virol; 2003 Jan; 69(1):1-6. PubMed ID: 12436471
[TBL] [Abstract][Full Text] [Related]
7. Human immunodeficiency virus type 1 fitness and tropism: concept, quantification, and clinical relevance.
Clementi M; Lazzarin A
Clin Microbiol Infect; 2010 Oct; 16(10):1532-8. PubMed ID: 20678176
[TBL] [Abstract][Full Text] [Related]
8. The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates.
Buzón MJ; Dalmau J; Puertas MC; Puig J; Clotet B; Martinez-Picado J
AIDS; 2010 Jan; 24(1):17-25. PubMed ID: 19770695
[TBL] [Abstract][Full Text] [Related]
9. Perspectives and opportunities for novel antiviral treatments targeting virus fitness.
Clementi M
Clin Microbiol Infect; 2008 Jul; 14(7):629-31. PubMed ID: 18190573
[TBL] [Abstract][Full Text] [Related]
10. The clinical significance of viral fitness.
Geretti AM
J HIV Ther; 2005 Mar; 10(1):6-10. PubMed ID: 15951728
[TBL] [Abstract][Full Text] [Related]
11. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
[TBL] [Abstract][Full Text] [Related]
12. In vivo dynamics of the K103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in Human Immunodeficiency Virus-infected patients.
Gianotti N; Galli L; Boeri E; Maillard M; Serra G; Ratti D; Gallotta G; Vacchini D; Tremolada Y; Lazzarin A; Clementi M; Castagna A
New Microbiol; 2005 Oct; 28(4):319-26. PubMed ID: 16386016
[TBL] [Abstract][Full Text] [Related]
13. In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy.
Elbeik T; Hoo BS; Campodonico ME; Dileanis J; Fay FF; Bortolozzi RL; Benetti MS; Fay OH; Marlowe N; Petrauskene O; Chernoff D; Smith L; Ng VL
J Hum Virol; 2001; 4(6):317-28. PubMed ID: 12082398
[TBL] [Abstract][Full Text] [Related]
14. Rapid selection of drug-resistant HIV-1 during the first months of suppressive ART in treatment-naive patients.
Metzner KJ; Allers K; Rauch P; Harrer T
AIDS; 2007 Mar; 21(6):703-11. PubMed ID: 17413691
[TBL] [Abstract][Full Text] [Related]
15. Rationale for maintenance of the M184v resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients.
Turner D; Brenner BG; Routy JP; Petrella M; Wainberg MA
New Microbiol; 2004 Apr; 27(2 Suppl 1):31-9. PubMed ID: 15646062
[TBL] [Abstract][Full Text] [Related]
16. Processivity and drug-dependence of HIV-1 protease: determinants of viral fitness in variants resistant to protease inhibitors.
Menzo S; Monachetti A; Balotta C; Corvasce S; Rusconi S; Paolucci S; Baldanti F; Bagnarelli P; Clementi M
AIDS; 2003 Mar; 17(5):663-71. PubMed ID: 12646788
[TBL] [Abstract][Full Text] [Related]
17. Evolutionary pathways of transmitted drug-resistant HIV-1.
Pingen M; Nijhuis M; de Bruijn JA; Boucher CA; Wensing AM
J Antimicrob Chemother; 2011 Jul; 66(7):1467-80. PubMed ID: 21502281
[TBL] [Abstract][Full Text] [Related]
18. HIV type-1 genotypic resistance profiles in vertically infected patients from Argentina reveal an association between K103N+L100I and L74V mutations.
Aulicino PC; Rocco CA; Mecikovsky D; Bologna R; Mangano A; Sen L
Antivir Ther; 2010; 15(4):641-50. PubMed ID: 20587857
[TBL] [Abstract][Full Text] [Related]
19. The host environment drives HIV-1 fitness.
van Opijnen T; Berkhout B
Rev Med Virol; 2005; 15(4):219-33. PubMed ID: 15942979
[TBL] [Abstract][Full Text] [Related]
20. Minority report: hidden memory genomes in HIV-1 quasispecies and possible clinical implications.
Briones C; Domingo E
AIDS Rev; 2008; 10(2):93-109. PubMed ID: 18615120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
